The molecular biology of dilated cardiomyopathy

European Heart Journal, Supplement

Volumn 4, Issue I, 2002, Pages

  Bowles, N E ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cardiomyopathy; Cytoskeleton; Genetics

Indexed keywords

DYSTROPHIN;

AUTOSOMAL DOMINANT DISORDER; CONFERENCE PAPER; GENETIC DISORDER; GENETICS; HEART DILATATION; HEART LEFT VENTRICLE; HEART VENTRICLE REMODELING; HUMAN; IMMUNOHISTOCHEMISTRY; MOLECULAR BIOLOGY; MYOPATHY; PRIORITY JOURNAL; X CHROMOSOME LINKED DISORDER;

EID: 0036900046     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1520-765X(02)90103-3     Document Type: Conference Paper

References (54)

1. O'Connell JB, Bristow MR. Economic impact of heart failure in the United States: Time for a different approach. J Heart Lung Transplant 1994; 13: S107-12.
2. Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation 1996; 93: 841-2.
3. Gillum RF. Idiopathic cardiomyopathy in the United States, 1970-1982. Am Heart J 1986; 111: 752-5.
4. Abelmann WH, Lorell BH. The challenge of cardiomyopathy. J Am Coll Cardiol 1989; 13: 1219-39.
5. Codd MB, Sugrue DD, Gersh BJ, et al. Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population-based study in Olmsted County, Minnesota, 1975-1984. Circulation 1989; 80: 564-72.
6. Grunig E, Tasman JA, Kucherer H, et al. Frequency and phenotypes of familial dilated cardiomyopathy. J Am Coll Cardiol 1998; 31: 186-94.
7. Berko BA, Swift M. X-linked dilated cardiomyopathy. N Engl J Med 1987; 316: 1186-91.
8. Towbin JA, Hejtmancik JF, Brink P, et al. X-linked dilated cardiomyopathy. Molecular genetic evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus. Circulation. 1993; 87: 1854-65.
9. Muntoni F, Cau M, Ganau A, et al. Brief report: Deletion of the dystrophin muscle-promoter region associated with X-linked dilated cardiomyopathy. N Engl J Med. 1993; 329: 921-5.
10. Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: The protein product of the Duchenne muscular dystrophy locus. Cell 1987; 51: 919-28.
11. Campbell KP, Kahl SD. Association of dystrophin and an integral membrane glycoprotein. Nature 1989; 338: 259-62.
12. Meng H, Leddy JJ, Frank J, et al. The association of cardiac dystrophin with myofibrils/Z-disc regions in cardiac muscle suggests a novel role in the contractile apparatus. J Biol Chem 1996; 271: 12364-71.
13. Cox GF, Kunkel LM. Dystrophies and heart disease. Curr Opin Cardiol 1997; 12: 329-43.
14. Petrof BJ, Shrager JB, Stedman HH, et al. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci USA 1993; 90: 3710-4.
15. Barth PG, Scholte HR, Berden JA, et al. An X-linked mitochondrial disease affecting cardiac muscle, skeletal muscle and neutrophil leucocytes. J Neurol Sci 1983; 62: 327-55.
16. Kelley RI, Cheatham JP, Clark BJ, et al. X-linked dilated cardiomyopathy with neutropenia, growth retardation, and 3-methylglutaconic aciduria. J Pediatr 1991; 119: 738-47.
17. Bione S, D'Adamo P, Maestrini E, et al. A novel X-linked gene, G4.5 is responsible for Barth syndrome. Nat Genet 1996; 12: 385-9.
18. D'Adamo P, Fassone L, Gedeon A, et al. The X-linked gene G4.5 is responsible for different infantile dilated cardiomyopathies. Am J Hum Genet 1997; 61: 862-7.
19. Bleyl SB, Mumford BR, Thompson V, et al. Neonatal, lethal noncompaction of the left ventricular myocardium is allelic with Barth syndrome. Am J Hum Genet 1997; 61: 868-72.
20. Olson TM, Michels VV, Thibodeau SN, et al. Actin mutations in dilated cardiomyopathy, a heritable form of heart failure. Science 1998; 280: 750-2.
21. Li D, Tapscoft T, Gonzalez O, et al. Desmin mutation responsible for idiopathic dilated cardiomyopathy. Circulation 1999; 100: 461-4.
22. Tsubata S, Bowles KR, Vatta M, et al. Mutations in the human delta-sarcoglycan gene in familial and sporadic dilated cardiomyopathy. J Clin Invest 2000; 106: 655-62.
23. Barresi R, Di Blasi C, Negri T, et al. Disruption of heart sarcoglycan complex and severe cardiomyopathy caused by beta sarcoglycan mutations. J Med Genet 2000; 37: 102-7.
24. Kamisago M, Sharma SD, DePalma SR, et al. Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy. N Engl J Med 2000; 343: 1688-96.
25. Olson TM, Kishimoto NY, Whitby FG, et al. Mutations that alter the surface charge of alpha-tropomyosin are associated with dilated cardiomyopathy. J Mol Cell Cardiol 2001; 33: 723-32.
26. Gerull B, Gramlich M, Atherton J, et al. Mutations of TTN, encoding the giant muscle filament titin, cause familial dilated cardiomyopathy. Nat Genet 2002; 30: 201-4.
27. Olson TM, Illenberger S, Kishimoto NY, et al. Metavinculin mutations alter actin interaction in dilated cardiomyopathy. Circulation 2002; 105: 431-7.
28. Mogensen J, Klausen IC, Pedersen AK, et al. Alpha-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy. J Clin Invest 1999; 103: R39-43.
29. 2+-desensitizing effect of a deletion mutation Delta K210 in cardiac troponin T that causes familial dilated cardiomyopathy. Proc Natl Acad Sci USA 2002; 99: 913-8.
30. Thierfelder L, Watkins H, MacRae C, et al. Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: A disease of the sarcomere. Cell 1994; 77: 701-12.
31. Dalakas MC, Park KY, Semino-Mora C, et al. Desmin myopathy, a skeletal myopathy with cardiomyopathy caused by mutations in the desmin gene. N Engl J Med. 2000; 342: 770-80.
32. Goldfarb LG, Park KY, Cervenakova L, et al. Missense mutations in desmin associated with familial cardiac and skeletal myopathy. Nat Genet 1998; 19: 402-3.
33. Munoz-Marmol AM, Strasser G, Isamat M, et al. A dysfunctional desmin mutation in a patient with severe generalized myopathy. Proc Natl Acad Sci USA 1998; 95: 11312-7.
34. Sjoberg G, Saavedra-Matiz CA, Rosen DR, et al. A missense mutation in the desmin rod domain is associated with autosomal dominant distal myopathy, and exerts a dominant negative effect on filament formation. Hum Mol Genet 1999; 8: 2191-8.
35. Hack AA, Groh ME, McNally EM. Sarcoglycans in muscular dystrophy. Microsc Res Tech 2000; 48: 167-80.
36. Kass S, MacRae C, Graber HL, et al. A gene defect that causes conduction system disease and dilated cardiomyopathy maps to chromosome 1p14q1. Nat Genet 1994; 7: 546-51.
37. Jung M, Poepping I, Perrot A, et al. Investigation of a family with autosomal dominant dilated cardiomyopathy defines a novel locus on chromosome 2q14-q22. Am J Hum Genet 1999; 65: 1068-77.
38. Olson TM, Keating MT. Mapping a cardiomyopathy locus to chromosome 3p22-p25. J Clin Invest 1996; 97: 528-32.
39. Messina DN, Speer MC, Pericak-Vance MA, et al. Linkage of familial dilated cardiomyopathy with conduction defect and muscular dystrophy to chromosome 6q23. Am J Hum Genet 1997; 61: 909-17.
40. Fatkin D, MacRae C, Sasaki T, et al. Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N Engl J Med 1999; 341: 1715-24.
41. Brodsky GL, Muntoni F, Miocic S, et al. Lamin A/C gene mutation associated with dilated cardiomyopathy with variable skeletal muscle involvement. Circulation 2000; 101: 473-6.
42. Chin TK, Perloff JK, Williams RG, et al. Isolated noncompaction of left ventricular myocardium. A study of eight cases. Circulation 1990; 82: 507-13.
43. Ichida F, Hamamichi Y, Miyawaki T, et al. Clinical features of isolated noncompaction of the ventricular myocardium: Long-term clinical course, hemodynamic properties, and genetic background. J Am Coll Cardiol 1999; 34: 233-40.
44. Bleyl SB, Mumford BR, Brown-Harrison MC, et al. Xq28-linked noncompaction of the left ventricular myocardium: Prenatal diagnosis and pathologic analysis of affected individuals. Am J Med Genet 1997; 72: 257-65.
45. Ichida F, Tsubata S, Bowles KR, et al. Novel gene mutations in patients with left ventricular noncompaction or Barth syndrome. Circulation 2001; 103: 1256-63.
46. Grady RM, Grange RW, Lau KS, et al. Role for alpha-dystrobrévin in the pathogenesis of dystrophin-dependent muscular dystrophies. Nat Cell Biol 1999; 1: 215-20.
47. Vatta M, Stetson SJ, Perez-Verdia A, et al. Molecular remodelling of dystrophin in patients with end-stage cardiomyopathies and reversal in patients on assistance-device therapy. Lancet 2002; 359: 936-41.
48. Thomas CV, Coker ML, Zellner JL, et al. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation 1998; 97: 1708-15.
49. Narula J, Pandey P, Arbustini E, et al. Apoptosis in heart failure: Release of cytochrome c from mitochondria and activation of caspase-3 in human cardiomyopathy. Proc Natl Acad Sci USA 1999; 96: 8144-9.
50. Di Bella I, Pagani F, Banfi C, et al. Results with the Novacor assist system and evaluation of long-term assistance. Eur J Cardiothorac Surg 2000; 18: 112-6.
51. Helman DN, Maybaum SW, Morales DL, et al. Recurrent remodeling after ventricular assistance: Is long-term myocardial recovery attainable? Ann Thorac Surg 2000; 70: 1255-8.
52. Helman DN, Addonizio LJ, Morales DL, et al. Implantable left ventricular assist devices can successfully bridge adolescent patients to transplant. J Heart Lung Transplant 2000; 19: 121-6.
53. Levin HR, Oz MC, Chen JM, et al. Reversal of chronic ventricular dilation in patients with end-stage cardiomyopathy by prolonged mechanical unloading. Circulation 1995; 91: 2717-20.
54. Zafeiridis A, Jeevanandam V, Houser SR, et al. Regression of cellular hypertrophy after left ventricular assist device support. Circulation 1998; 98: 656-62.